UPDATED May 20, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | kr235.91 | 12.3% | -27.3% | kr20.7b | kr368.55 | PS82.1x | E63.5% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.20 | 0% | -24.9% | €212.6m | €5.72 | PS3.2x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.25 | -5.1% | 58.5% | US$286.1m | US$9.23 | PB1.5x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
0EVI | €2.61 | 13.8% | -4.1% | €212.6m | €6.21 | PS3.4x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.93 | 1.8% | 122.1% | US$1.9b | US$13.83 | PS11.7x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | kr21.70 | 14.9% | n/a | kr20.7b | kr34.52 | PS80.6x | E63.5% | 0% | Pharmaceuticals & Biotech | ||
IPHA | €2.85 | 9.2% | 1.2% | €212.6m | €6.79 | PS3.4x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$4.03 | 8.9% | -58.7% | US$234.7m | US$9.25 | PB2.1x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$3.16 | 3.3% | 117.9% | US$118.3m | US$15.00 | PB12.5x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$9.19 | 3.4% | 1.1% | US$875.0m | US$19.00 | PS89046.7x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$6.17 | -2.7% | -63.6% | US$461.3m | US$14.86 | PS3x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$4.55 | -1.5% | 58.0% | US$236.8m | US$8.50 | PS2.8x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$6.30 | 15.8% | 35.2% | US$195.3m | US$19.80 | PS7.3x | E66.2% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$47.01 | 9.8% | 792.0% | US$1.7b | US$68.14 | PB11.9x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.54 | 7.8% | -22.5% | US$367.2m | US$21.20 | PS31.3x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$8.17 | -2.2% | -28.5% | US$213.4m | US$23.44 | PS4.2x | E60.2% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$232.10 | 9.8% | -18.7% | US$4.7b | US$363.86 | PB5.8x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$15.10 | -0.5% | -39.1% | US$2.4b | US$27.16 | PS3.1x | E40.8% | n/a | Pharmaceuticals & Biotech |